Structure Therapeutics reported Phase 2 data in March 2026 from its aleniglipron programme showing weight loss of up to 16.3% at 44 weeks, the highest efficacy yet reported for an oral small-molecule GLP-1 receptor agonist at that time point
No single medication suits everyone, and individual factors affect both efficacy and tolerability
A GLP-1 tracker helps people track medications like Ozempic, Wegovy, Zepbound, and Mounjaro
With three or more injections per week, incorporate the thighs and upper arms into your rotation to prevent tissue irritation and lipodystrophy at overused sites
The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with obesity and established cardiovascular disease
[DOI] [PubMed] [Google Scholar] 103.Vinuesa A., Pomilio C., Gregosa A., Bentivegna M., Presa J., Bellotto M., Saravia F., Beauquis J